BioCentury
ARTICLE | Clinical News

FP 250: Phase I data

April 2, 2012 7:00 AM UTC

An open-label, crossover Phase I trial in 12 healthy volunteers showed that single doses of FP 250 led to significantly higher systemic exposure and plasma concentrations of fenofibric acid compared ...